Hyperion DeFi (HYPD) Competitors $7.08 -1.18 (-14.29%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HYPD vs. PBYI, NVCT, CCCC, ACOG, ENTA, MOLN, GLSI, CTOR, NKTX, and KRROShould you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Puma Biotechnology (PBYI), Nuvectis Pharma (NVCT), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Enanta Pharmaceuticals (ENTA), Molecular Partners (MOLN), Greenwich LifeSciences (GLSI), Citius Oncology (CTOR), Nkarta (NKTX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Hyperion DeFi vs. Its Competitors Puma Biotechnology Nuvectis Pharma C4 Therapeutics Alpha Cognition Enanta Pharmaceuticals Molecular Partners Greenwich LifeSciences Citius Oncology Nkarta Korro Bio Puma Biotechnology (NASDAQ:PBYI) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Do institutionals & insiders have more ownership in PBYI or HYPD? 61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 23.3% of Puma Biotechnology shares are held by insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, PBYI or HYPD? Puma Biotechnology has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Is PBYI or HYPD more profitable? Puma Biotechnology has a net margin of 16.37% compared to Hyperion DeFi's net margin of -62,238.41%. Puma Biotechnology's return on equity of 49.35% beat Hyperion DeFi's return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology16.37% 49.35% 18.25% Hyperion DeFi -62,238.41%N/A -316.90% Which has higher valuation and earnings, PBYI or HYPD? Puma Biotechnology has higher revenue and earnings than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$230.50M0.66$30.28M$0.773.99Hyperion DeFi$60K660.80-$49.82M-$58.40-0.12 Do analysts rate PBYI or HYPD? Puma Biotechnology presently has a consensus price target of $7.00, suggesting a potential upside of 128.01%. Hyperion DeFi has a consensus price target of $2.00, suggesting a potential downside of 71.75%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Puma Biotechnology is more favorable than Hyperion DeFi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hyperion DeFi 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer PBYI or HYPD? In the previous week, Hyperion DeFi had 4 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Hyperion DeFi and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 beat Hyperion DeFi's score of -0.06 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperion DeFi 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPuma Biotechnology beats Hyperion DeFi on 13 of the 16 factors compared between the two stocks. Get Hyperion DeFi News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPD vs. The Competition Export to ExcelMetricHyperion DeFiBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.28M$134.47M$5.48B$9.51BDividend YieldN/A3.74%4.73%4.08%P/E Ratio-0.123.7828.6723.80Price / Sales660.804,246.60373.9066.65Price / CashN/A13.1935.4557.96Price / Book-0.0139.388.275.55Net Income-$49.82M-$90.99M$3.24B$259.03M7 Day Performance-8.05%-1.82%-3.69%-4.59%1 Month Performance-55.25%11.25%4.33%4.46%1 Year Performance-91.73%189.83%25.95%18.03% Hyperion DeFi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPDHyperion DeFi0.3788 of 5 stars$7.08-14.3%$2.00-71.8%-92.4%$46.28M$60K-0.1240News CoverageGap DownPBYIPuma Biotechnology3.6428 of 5 stars$3.34+1.8%$7.00+109.6%-12.3%$162.79M$230.50M4.34200Upcoming EarningsNVCTNuvectis Pharma2.5676 of 5 stars$7.60-2.3%$17.00+123.7%+10.0%$162.55MN/A-6.738News CoverageUpcoming EarningsAnalyst RevisionCCCCC4 Therapeutics2.3838 of 5 stars$2.18-3.5%$12.00+450.5%-68.3%$160.48M$35.58M-1.48150News CoverageUpcoming EarningsACOGAlpha Cognition1.2089 of 5 stars$9.73-2.4%$20.00+105.5%N/A$159.72MN/A-8.11N/APositive NewsENTAEnanta Pharmaceuticals3.5783 of 5 stars$8.03+8.5%$18.50+130.4%-52.0%$158.19M$67.64M-1.77160News CoverageUpcoming EarningsAnalyst RevisionGap DownMOLNMolecular Partners2.1631 of 5 stars$3.88+0.3%$12.00+209.3%-55.9%$156.19M$5.65M-2.02180Gap DownGLSIGreenwich LifeSciences1.3032 of 5 stars$11.55-0.2%$39.00+237.7%-28.4%$154.67MN/A-9.173Positive NewsCTORCitius Oncology1.3467 of 5 stars$1.87-5.1%$3.00+60.4%N/A$154.39MN/A0.00N/ANKTXNkarta2.416 of 5 stars$2.20+1.9%$14.33+551.5%-66.9%$153.27MN/A-1.46140News CoverageKRROKorro Bio1.3162 of 5 stars$15.61-2.5%$102.43+556.2%-68.2%$150.34M$2.27M-1.6570 Related Companies and Tools Related Companies PBYI Competitors NVCT Competitors CCCC Competitors ACOG Competitors ENTA Competitors MOLN Competitors GLSI Competitors CTOR Competitors NKTX Competitors KRRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HYPD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperion DeFi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperion DeFi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
